Latest news and press releases about Contineum Therapeutics, Inc. (CTNM): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Price
| Price | $13.76 |
| Market Cap | $518M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.04 |
| EV / EBITDA | -9.40 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -24.73% |
| Return on Invested Capital | -26.96% |
| Return on Assets | -22.99% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACIU · ALDX · AMRN · ANRO · CADL · CAPR · KYTX
Explore sector: Healthcare · Biotechnology
More sections of CTNM: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks